Pharvaris N.V.

NASDAQ:PHVS

18.53 (USD) • At close January 3, 2025
Bedrijfsnaam Pharvaris N.V.
Symbool PHVS
Munteenheid USD
Prijs 18.53
Beurswaarde 1,000,762,681
Dividendpercentage 0%
52-weken bereik 15.37 - 33
Industrie Biotechnology
Sector Healthcare
CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA
Website https://pharvaris.com

An error occurred while fetching data.

Over Pharvaris N.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft

Vergelijkbare Aandelen

Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

1.02 USD

Kiniksa Pharmaceuticals, Ltd. logo

Kiniksa Pharmaceuticals, Ltd.

KNSA

20.31 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

1.525 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

9.62 USD

Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

RLMD

0.47 USD

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

1.55 USD

Aveanna Healthcare Holdings Inc. logo

Aveanna Healthcare Holdings Inc.

AVAH

4.66 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)